A clinical trial to compare the effects of ranitidine, pantoprazole, and sucralfate on the prevention of gastrointestinal bleeding and ventilator-associated pneumonia in children under mechanical ventilation.

Start Date20 Feb 2020

Sponsor / Collaborator

Mashhad University of Medical Sciences

KCT0005871 / TerminatedPhase 4IIT

Influence of pretreatment with ranitidine bismuth citrate on the cure rates of Helicobacter pylori eradication

Start Date03 Jun 2019

Sponsor / Collaborator

Kyung Hee University Hospital at Gangdong

NCT02441673 / Unknown statusPhase 2IIT

Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering Following Subarachnoid Block

Post Anaesthetic Shivering is a common complication of Subarachnoid block. It is graded based on it's severity and has been known to cause various problems like patient's discomfort, hypoxia, change in hemodynamic variables of the patient and poor wound healing. This problem has been managed via pharmacologic and non-pharmacologic means. Non-pharmacologic modalities involve options aimed at warming the patient. Pharmacologically, opioids are used more commonly to prevent and treat this condition. This then introduces the side effect of nausea/vomiting and sedation which may reduce overall patient's satisfaction on the perception of the Subarachnoid block. It is for this reason that Nefopam - a centrally acting non-opioid, non-steroidal anti-inflammatory drug (NSAID) analgesic, relatively new drug in the Nigerian market with significant anti-shivering effect is compared with a well established opioid like Tramadol. Having similar cost profile, the option of replacing Tramadol with Nefopam especially in conditions where the patient is more hemodynamically unstable is considered in this project.

Start Date12 Oct 2018

Sponsor / Collaborator-

100 Clinical Results associated with Ranitidine Bismuth Citrate

100 Translational Medicine associated with Ranitidine Bismuth Citrate

100 Patents (Medical) associated with Ranitidine Bismuth Citrate

319

Literatures (Medical) associated with Ranitidine Bismuth Citrate

01 Mar 2024·Drugs in R&D

Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects

Article

Author: Gao, Li-Chen ; Dai, Shang-Ming ; Hu, Jin-Da ; Long, Hui-Zhi ; Cheng, Yan ; Luo, Hong-Yu ; Xu, Shuo-Guo ; Zhou, Zi-Wei ; Li, Feng-Jiao ; Su, Yu

BACKGROUND:

Potassium bismuth citrate is a gastric mucosal protector and a key drug for treating peptic ulcers.

OBJECTIVE:

To evaluate the pharmacokinetic characteristics and safety of 120-mg bismuth potassium citrate formulations administered orally under fasting conditions in healthy Chinese subjects.

METHOD:

A single-center open two-cycle trial was conducted on 12 healthy subjects who received a single oral dose of 120 mg of bismuth potassium citrate. The plasma concentration of bismuth was determined using a validated inductively coupled plasma mass spectrometry (ICP‒MS) method. The pharmacokinetic parameters, including maximum serum concentration (C_max) and area under the curve concentration-time curve (AUC_0-t and AUC_0-∞), and safety were evaluated via noncompartment analysis.

RESULTS:

The ratios of the least square geometric mean ratio between the test (T) and reference (R) formulations for C_max, AUC_0-t, and AUC_0-∞ were 44.8%, 55.5%, and 64.4%, respectively; the bilateral 95% confidence intervals (Cis) for these parameters were 20.2-99.6%, 24.1-127.5%, and 23.7-175.0%, respectively, and the non-inferior limits for these parameters were 169.4%, 198.8%, and 200.5%, respectively. The upper limits of the one-sided 97.5% confidence interval for the least squares geometric mean ratio (T/R) were lower than the non-inferior limits. No serious adverse reactions or adverse reactions leading to detachment were observed among the subjects.

CONCLUSION:

The concentration of bismuth in the blood of healthy subjects in the T formulation was not greater than that in the R formulation. Similarly, the safety of oral administration of 120 mg of bismuth potassium citrate formulations to healthy subjects was good. The trial registration number (TRN) was [2018] 013, 6 December 2018.

01 Jan 2024·Therapeutic Advances in Gastroenterology

Clarithromycin sustained-release tablet may be an improper therapy for the eradication of Helicobacter pylori

Article

Author: Zuo, Xingsheng ; Zhao, Chenglong ; Wang, Yaqin ; Luo, Jing ; Shen, Qingli

Background::

Clarithromycin plays an important role in eradicating Helicobacter pylori ( H. pylori) through quadruple therapy. However, there is limited research on whether different forms of clarithromycin dosage have similar efficacies against H. pylori.

Objective::

We aimed to evaluate the efficacy of different forms of clarithromycin dosage in bismuth-containing quadruple therapy for eradicating H. pylori.

Design::

A single-center retrospective analysis comparing the efficacy of different forms of clarithromycin dosage in eradicating H. pylori.

Methods::

An analysis was conducted on patients diagnosed with H. pylori infection through the 13C-urea breath test (13C-UBT) at Henan Provincial People’s Hospital, China from 2020 to 2022 who were treated with either a dispersible or sustained-release clarithromycin tablet (500 mg each), alongside amoxicillin (1000 mg), a standard dose of proton pump inhibitors (PPIs), and bismuth citrate (220 mg), administered twice daily as part of bismuth-containing quadruple therapy. Treatment efficacy was assessed using 13C-UBT at least 4 weeks after treatment completion. The H. pylori eradication rate was the primary outcome of this study, and factors influencing it were analyzed.

Results::

Among 2094 screened patients, 307 with H. pylori infection (mean age, 41.8 ± 0.7 years; 43% men) received bismuth-containing quadruple therapy. Univariate analysis of the dispersible and sustained-release tablet groups revealed a lower eradication rate with the sustained-release tablet compared with the dispersible clarithromycin tablet regimen (75.26% (73/97) vs 95.26% (200/210), respectively; p < 0.05). Other factors, such as smoking, age, and PPI type, were not significantly associated with the cure rate. Multivariate analysis identified the form of clarithromycin dosage (dispersible vs sustained-release) to be an independent risk factor for eradication failure using the bismuth-containing quadruple therapy (odds ratio = 0.145, 95% confidence interval: (0.065–0.323); p < 0.05).

Conclusion::

The clarithromycin dispersible tablet demonstrated a higher H. pylori eradication rate, and the sustained-release clarithromycin tablet may be inappropriate for H. pylori eradication.

01 Jan 2021·The Tohoku journal of experimental medicineQ4 · MEDICINE

Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of <i>Helicobacter pylori</i> Eradication: A Prospective, Randomized, Controlled and Open-Label Study

Q4 · MEDICINE

Article

Author: Cha, Jae Myung ; Yoon, Jin Young ; Jeon, Jung Won ; Kwak, Min Seob

Effective Helicobacter pylori (H. pylori) eradication is a major public health concern; however, eradication failure rates with the standard triple therapy remain high. We aimed to investigate the effectiveness and tolerability of ranitidine bismuth citrate (RBC) pretreatment before standard triple therapy for H. pylori eradication. A prospective, randomized, controlled, and open-label clinical trial was conducted from June to December 2019. H. pylori eradication rate, safety, and tolerability were compared between the standard treatment group (esomeprazole, amoxicillin, and clarithromycin for 7 days) and RBC pretreatment group (RBC for 2 weeks before standard triple therapy). This trial ended earlier than estimated owing to the N-nitrosodimethylamine concerns with ranitidine. Success rates of H. pylori eradication were 80.9% and 67.3% in the RBC pretreatment (n = 47) and standard treatment (n = 52) (p = 0.126) groups, respectively. Our trial was discontinued earlier than planned; however, a statistical significance would be achieved by expansion of our data (p = 0.031) if patient enrollment numbers reached those initially planned. Adverse event rates were comparable between groups (25.5% in the pretreatment group vs. 28.8% in the standard treatment group), without serious event. Tolerability was excellent in both groups, recorded as 97.9% and 100% in the pretreatment and standard treatment groups, respectively. Compared with the standard triple regimen, RBC pretreatment for 2 weeks may achieve higher H. pylori eradication rates, with excellent safety and tolerability. However, this study necessitates further validation as it was discontinued early owing to the N-nitrosodimethylamine issues of ranitidine.

News (Medical) associated with Ranitidine Bismuth Citrate

28 Jul 2023

·www.jnj.com

Janssen Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy EDURANT ®

TITUSVILLE, N.J., July 28, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of EDURANT® (rilpivirine) to include the treatment of HIV-1 infection in children weighing 10 kg or more. A parallel Marketing Authorization application has also been submitted to the European Medicines Agency (EMA) in support of a type II variation and line extension for expanded pediatric use in Europe. These applications reflect Janssen’s longstanding commitment to address the needs of adults, adolescents and children affected by the global HIV epidemic.If the new applications are approved, EDURANT®, a product of Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, could be administered to younger pediatric patients via standard 25 mg tablets or new 2.5 mg tablets for oral dispersion that were developed to aid administration and weight-adjusted dosing for children. “We’ve been working to fight HIV for decades and are proud to have helped bring forward nine medicines for people living with HIV,” said Penny Heaton, M.D., Global Therapeutic Area Head, Infectious Diseases and Vaccines, Janssen Research & Development, LLC. “These filings are the latest example of our longstanding work to make different treatment options available to meet the diverse needs of people living with HIV.”The expanded pediatric applications are supported by data from the Phase 2 PAINT (NCT00799864) and PICTURE (NCT04012931) studies, which showed that EDURANT®, in combination with other antiretroviral therapies, effectively maintains or suppresses the virus in treatment-experienced and treatment-naive pediatric patients, respectively. Given these data, Janssen is seeking an expanded indication to allow use in treatment-naïve children (with HIV-1 RNA <100,000 copies/mL) and treatment-experienced virologically suppressed children (with HIV-1 RNA <50 copies/mL) weighing 10 kg or more.The expansion of the EDURANT® indication would mark the latest step forward in Janssen’s efforts to make its HIV medicines available to young people living with HIV. In 2022, the FDA approved the world’s first long-acting injectable HIV-1 treatment option for adolescents 12 years of age and older. This regimen consists of Janssen’s long-acting rilpivirine and ViiV Healthcare’s long-acting cabotegravir and requires as few as six treatments per year.Johnson & Johnson’s Commitment to HIVIn addition to driving innovation in HIV care, Johnson & Johnson also works with vulnerable communities on the global frontlines of the HIV epidemic, and has supported collaborative initiatives like Positively Fearless, the DREAMS Partnership and the MenStar Coalition. We also support the New Horizons Collaborative, which is working to address the unmet needs of HIV treatment-experienced children, adolescents and young adults in sub-Saharan Africa.To learn more about Johnson & Johnson’s commitment to combating HIV, please visit jnj.com/HIV.About EDURANT®EDURANT is a human immunodeficiency virus type 1 (HIV-1) specific, nonnucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients 12 years of age and older and weighing at least 35 kg with HIV-1 RNA less than or equal to 100,000 copies/mL. Limitations of Use:EDURANT is indicated in combination with VOCABRIA (cabotegravir), for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.Please see full Prescribing Information for important safety information.Important Safety InformationWho should not take EDURANT®?Do not take EDURANT® if you also take:What should I tell my healthcare provider before taking EDURANT®?Before taking EDURANT®, tell your healthcare provider about all your medical conditions, including if you:Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.Some medicines interact with EDURANT®. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine. You can ask your healthcare provider or pharmacist for a list of medicines that interact with EDURANT®.Do not start taking a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take EDURANT® with other medicines.How should I take EDURANT®?What are the possible side effects of EDURANT®?EDURANT® can cause serious side effects including:Stop taking EDURANT® and get medical help right away if you develop a rash with any of the following signs or symptoms:Liver problems. People with a history of hepatitis B or C virus infection or who have certain liver function test changes may have an increased risk of developing new or worsening liver problems during treatment with EDURANT®. Liver problems have also happened during treatment with EDURANT® in people without a history of liver disease. Your healthcare provider may need to do tests to check your liver enzymes before and during treatment with EDURANT®. Call your healthcare provider right away if you develop any of the following signs or symptoms of liver problems:Depression or mood changes. Tell your healthcare provider right away if you have any of the following symptoms:Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having any new symptoms after starting your HIV-1 medicine.The most common side effects of EDURANT® include depression, headache, trouble sleeping (insomnia), and rash.This is not a complete list of all side effects. If you experience these or other symptoms, contact your healthcare provider right away.You are encouraged to report side effects of prescription drugs to the FDA. www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Janssen Products, LP, at 1-800-JANSSEN (1-800-526-7736).Please read the full Product Information for EDURANT® and discuss any questions you have with your healthcare provider.About the Janssen Pharmaceutical Companies of Johnson & JohnsonAt Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.Learn more at http://www.janssen.com and follow us at http://www.twitter.com/JanssenGlobal and www.twitter.com/JanssenUS. Janssen Sciences Ireland Unlimited Company and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding rilpivirine and other treatments for HIV. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Sciences Ireland Unlimited Company, Janssen Research & Development, LLC, the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.###© Janssen Therapeutics, Division of Janssen Products, LP

Drug ApprovalPhase 2

05 Jul 2023

·www.biospace.com

Biopharma Lawsuit Tracker 2023: Alexion-Portola, Liquidia, and Others Under Scrutiny

Pictured: A wooden gavel on a table with a book in the background/iStock, nathaphat Between the hotly debated Inflation Reduction Act, tightening Federal Trade Commission regulation and ongoing patent battles, biopharma legal news is abundant. Here, we debut our new, exclusive Biopharma Lawsuit Tracker. Follow along as we keep you up to date on who’s headed to court and why, and let BioSpace be your news source for industry lawsuits through 2023. June June 30: Following a lawsuit filed by the FTC in May aiming to block a multi-billion-dollar merger between Amgen and Horizon, the companies have filed a counter suit against the FTC claiming the original suit is unconstitutional, Law360 reported on June 30. “The FTC’s case is wholly novel and impossibly speculative,” the companies wrote, according to Endpoints News. June 29: Alexion-Portola faced Securities and Exchange Commission (SEC) insider trading charges against a pharmaceutical executive, doctors and individuals involved in an alleged scheme surrounding the deal, as reported by several outlets. According to the SEC, Joseph Dupont, a former vice president at Alexion and member of the company's acquisitions team, is accused of initiating the tip-off. The charges, filed in the U.S. District Court for the Southern District of New York, assert that Dupont knowingly or recklessly shared confidential information about the acquisition with his close friends, who then passed it along to other associates. Liquidia intends to defend itself against a potential new patent related to United Therapeutics' treprostinil for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD) in response to an SEC filing. The two companies have been locked in an ongoing legal dispute over the drug. Liquidia stated in its SEC filing that United Therapeutics had received a notice of allowance for its patent application, which broadly covers the treatment of PH-ILD using an inhaled form of treprostinil. This notice indicates that the U.S. Patent and Trademark Office has determined that United Therapeutics is entitled to the patent. June 23: The Amgen-Horizon deal saw more scrutiny as six states joined the FTC in requesting the District Court of the Northern District of Illinois grant a preliminary injunction against the acquisition. This injunction would remain in effect while the FTC prepares an administrative complaint and until decisions are made regarding the complaint. June 21: PhRMA, Merck and Bristol-Myers Squibb have jointly filed a lawsuit against the federal government concerning the price-setting provisions outlined in the IRA. The lobbying group and the two pharmaceutical companies have come together in their legal action, claiming that the legislation violates the U.S. Constitution. Novo Nordisk initiated lawsuits against medical spas, wellness and weight loss clinics and pharmacies. The lawsuits allege that these establishments have been advertising and selling products containing semaglutide, the active ingredient found in Novo Nordisk's diabetes medications Ozempic and Rybelsus, as well as the weight loss injection Wegovy. June 20: Sanofi announced that an arbitration tribunal from the International Chamber of Commerce had dismissed a claim made by Boehringer Ingelheim. The claim was related to legal responsibilities associated with the ranitidine-based product Zantac. BioNTech, a German company specializing in mRNA-based vaccines, is facing its first lawsuit in Germany related to alleged side effects of its COVID-19 vaccine, developed in partnership with Pfizer and authorized for emergency use in 158 countries. June 19: Bristol Myers Squibb (BMS) filed a lawsuit against the Biden administration. The lawsuit contends that an upcoming Medicare drug negotiation program via the IRA infringes upon the First and Fifth Amendments of the U.S. Constitution. June 15: AbbVie initiated a lawsuit alleging patent infringement by China-based BeiGene regarding their new blood cancer drug, Brukinsa (zanubrutinib). The lawsuit claims that Brukinsa infringes on AbbVie’s patent for Imbruvica (ibrutinib), a drug developed in collaboration with Janssen and AbbVie’s Pharmacyclics. Imbruvica received FDA approval in 2014 as a therapy for chronic lymphocytic leukemia. June 12: The U.S. Chamber of Commerce has filed a lawsuit in federal court against the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS). The lawsuit challenges the constitutionality of the drug price negotiation program outlined in the IRA. June 9: Pharmacies and drug manufacturers Allergan and Teva Pharmaceuticals, along with retail chains CVS, Walgreens, and Walmart,have agreed to pay state and local governments an additional $18.75 billion to resolve lawsuits accusing them of fueling the opioid epidemic. After a two-month trial, Walgreens agreed to pay $500 million settlement to the state of New Mexico for failing to recognize abuse of opioid prescriptions. June 8: Eli Lilly and Takeda were hit with a class action suit accusing the pharmaceutical companies of racketeering, certified by a California Federal Judge. The allegations stem from the companies' purported failure to disclose the risk of bladder cancer associated with their diabetes drug, Actos (pioglitazone), during its marketing. June 7: Promosome filed individual lawsuits against Moderna and Pfizer. The lawsuits allege that both companies infringed upon patent protections associated with mRNA technology. In the filings presented to the Southern District Court of California, Promosome asserted that its affiliated scientists made a breakthrough in 2009. They reportedly discovered a method for enhancing protein expression by making minor modifications to mRNA. This is the latest in a growing number of patent suits over the COVID mRNA vaccines. June 6: Merck initiated a lawsuit against the Biden administration in the U.S. District Court for the District of Columbia. The lawsuit challenges the IRA’s constitutionality, encompassing provisions related to drug price negotiation. Lisa Munger is a senior editor at BioSpace. You can reach her at lisa.munger@biospace.com. Follow her on LinkedIn.

Drug ApprovalVaccinePatent InfringementAcquisitionmRNA

23 Jun 2023

·www.fiercepharma.com

GSK escapes first state-level Zantac jury trial with settlement

The settlement comes after fellow former Zantac makers Sanofi and Pfizer struck a deal with the plaintiff in December. A month before it was set to take the stand in the highly anticipated first Zantac-related trial, GSK scratched the case with a settlement. The company reached a confidential deal with Californian James Goetz, who claimed that he developed bladder cancer after taking now-discontinued heartburn med Zantac. The case would have served as the opener to thousands of state-level Zantac cases. The settlement “reflects the company’s desire to avoid distracted related to protracted litigation” in the case, GSK in a statement. “GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases,” it added. Goetz also sued Sanofi and Pfizer, both of which reached settlements last December. At the time, GSK said in a statement that it would defend itself in “all claims brought at the state level,” arguing that there is “no consistent or reliable evidence” that the drug causes cancer. The case was pushed back to July 24 in February, giving judge Evelio Grillo more time to weigh both side’s expert testimonies. In March, the judge moved to allow the expert testimony, which GSK said it “respectfully disagreed” with in a statement, pointing to the 13 epidemiological studies evaluating human data in ranitidine use in which “scientific consensus is that there is no consistent or reliable evidence,” the company alleged. Last month, GSK saw a win in a key class-action suit in Canada after the British Columbia Supreme Court dismissed the litigation. That decision was made due to “uncontroverted evidence that neither ranitidine nor NDMA are reliably associated with increased cancer risk,” GSK said in its statement at the time. But the biggest win so far came in December when a U.S. District Judge wiped thousands of federal claims from GSK, Sanofi, Pfizer and Boehringer Ingelheim’s plates, ruling that the science used to back up the plaintiff’s claims utilized “unreliable methodologies” to reach their conclusions. Zantac, or ranitidine, cases have been looming since 2020, when the FDA asked the drug’s makers to voluntarily recall their products following a 2019 discovery of high levels of a likely carcinogen in the pill and its generics. While GSK claims the evidence of the med causing cancer doesn’t stack up, a February Bloomberg report alleged that the company was warned by its own scientists as well as independent researchers about the potential cancer-causing impurity. A company spokesperson called the article “an incomplete and biased presentation of facts.” Now, most of the pending Zantac litigation in the U.S. will take place in Delaware with more than 75,000 state cases. Those will likely begin in January, Reuters reports.

Patent Infringement

100 Deals associated with Ranitidine Bismuth Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D05699	Ranitidine Bismuth Citrate	A02BA02	DBSALT001128

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Erosive esophagitis	US	GSK Plc	23 Mar 1998
Gastroesophageal Reflux	US	GSK Plc	23 Mar 1998
Zollinger-Ellison Syndrome	US	GSK Plc	23 Mar 1998
Helicobacter Infections	GB	GSK Plc	23 Sep 1995
Stomach Ulcer	GB	GSK Plc	18 Sep 1995
Duodenal Ulcer	GB	GSK Plc	13 Sep 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heartburn	Phase 2	AU	GSK Plc	01 May 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01896557 (CTgov)	Phase 4	Coronary Artery Disease \| Medication interactions	92	clopidogrel+omeprazole (Omeprazole)	tzfardfwfy(lbkptkxugv) = hstfaiczff jqinuiarcp (nakwxpzlwl, euikvxcevi - kqrjvkugiq) View more	-	23 May 2016
				clopidogrel+Ranitidine (Ranitidine)	tzfardfwfy(lbkptkxugv) = vgqicklbxb jqinuiarcp (nakwxpzlwl, fpuwncland - afyvlgjygs) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis